ScreenerHero

ODTX Odyssey Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · odysseytx.com
18.08USD-0.28%Mkt Cap: 868.90M $P/E: —

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-inte…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap868.90M USD
Enterprise Value583.01M USD
Revenue (TTM)99.00K USD
Gross Profit-120.62M USD
Net Income (TTM)-148.65M USD
Revenue/Share0.0090 USD
Last Price18.08 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees100
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.16
PEG—
EV/EBITDA-3.88
EV/Revenue5889.01
P/S8801.02
P/B2.06
EPS (TTM)-6.53
EPS (Forward)-4.36
52W Range
15.1021% of range29.05
52W High29.05 USD
52W Low15.10 USD
Profitability
Gross Margin0.00%
Oper. Margin-156392.92%
EBITDA Margin0.00%
Profit Margin-4994.86%
ROE30.44%
ROA-55.10%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-129.47M USD
CapEx (TTM)1.23M USD
FCF Margin—
FCF Yield—
Net Debt-285.75M USD
Net Debt/EBITDA1.90
Balance Sheet
Debt/Equity-0.06
Current Ratio11.36
Quick Ratio10.98
Book Value/Sh8.79 USD
Cash/Share6.48 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)35.75 USD
Upside (mean)+97.7%
Target Range29.00 USD – 44.00 USD
29.00+97.7% to mean44.00
# Analysts4
Ownership
Shares Out.48.06M
Float20.05M
Insiders6.19%
Institutions83.10%
Short Interest
Short Ratio11.6d
Short % Float5.24%
Short % Out.4.60%
Shares Short2.21M
Short (prev mo.)2.25M
Technical
SMA 5022.58 (-19.9%)
SMA 20019.93 (-9.3%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)347.94K
Avg Vol (10d)286.59K
Technical Indicators
RSI (14)35.6
MACD-1.0904
MACD Signal-0.6129
MACD Hist.-0.4774
BB Upper25.70 USD
BB Middle21.86 USD
BB Lower18.02 USD
BB Width35.13%
ATR (14)1.881 USD
Vol Ratio (20d)0.62x